Q2 2021

Filed Jul 30, 2021 · 10-Q · 30 days after period end · 0001213900-21-039595

Q2 2021 · 10-Q

Revenue

$266.00K

no prior Q2 2020 on file

Net Income

-$5.02M

N/M vs Q2 2020

EPS Diluted

-$0.25

N/M vs Q2 2020

Operating Income-$5,075,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2021	Q2 2020	Q2 2019	Q2 2018
Revenue	$266.00K	—	—	—
Net Income	-$5.02M	-$4.63M	-$5.03M	-$4.86M
EPS Diluted	-$0.25	-$0.41	-$1.00	-$0.04

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR